Maxion Therapeutics, a Cambridge, UK-based biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, raised $72M (£58M) in Series A funding.
The round was led by General Catalyst with participation from new investors British Patient Capital, Solasta Ventures and Eli Lilly and Company and existing investors LifeArc Ventures, Monograph Capital and BGF.
The company intends to use the funds to accelerate its expansion into a clinical-stage biotech company, taking the lead KnotBody programme MAX001 to clinical proof-of-concept and advancing additional programmes towards the clinic.
Founded in 2020 by Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO, and led by CEO Arndt Schottelius, Maxion Therapeutics is a biotechnology company developing antibody-based drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease. It is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using phage and mammalian display technologies.
FinSMEs
17/03/2025